Keywords
Pharmacotherapy
Metoprolol
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To evaluate the pharmacotherapy profile of patients with Cardiac Insufficiency (CI) registered in the Metoprolol use protocol, linked to Family Pharmacies, in a municipality in the interior of Bahia, regarding the doses used, comparing with the recommendations of the target dose of the Brazilian Guideline for HF. Methods: This is a quantitative, descriptive, cross-sectional study carried out with patients registered in the Metoprolol Use Protocol, linked to Family Pharmacies in a municipality in the interior of Bahia, through the application of a semi-structured questionnaire. Results: Of the study participants (n=37), only 5.4% (2), 51.4% (19) and 16.2% (6) were using the recommended target dose of beta-blocker (Metoprolol), an inhibitor of angiotensin-converting enzyme (ACE) or angiotensin receptor blocker (ARB) and mineralocorticoid receptor antagonist (MRA), respectively Conclusion: There is a relevant discrepancy between the recommendations of the Brazilian Guideline and clinical practice, regarding the pharmacological classes to be used , and especially regarding the target dose of such drugs, even when there is a good level of evidence. This fact can have a negative impact on the survival of these patients, therefore, actions are needed to improve adherence to recommended therapeutic classes, as well as dose titration in order to reach the target or recommended dose.
References
BARRIOS V, et al. Manejo de los pacientes con insuficiencia cardíaca atendidos en la consulta de cardiología: EstudioIC-BERG. Rev Clin Esp, 2020; 220(6): 339-349.
BIONDI BB, et al. Tratamento da ICC com valsartana e sacubitril. Revista Caderno de Medicina, 2019; 2(1): 1-10.
BRUNNER-LA RHP, et al. Contemporary drug treatment of chronic heart failure with reduced ejection fraction: the CHECK-HF registry. JACC Heart Fail, 2019; 7(1): 13-21.
CALLES CAN, et al. Correlação entre a qualidade de vida e a classificação funcional em pacientes com insuficiência cardíaca congestiva em internamento hospitalar. Cadernos de Graduação - Ciências Biológicas e da Saúde Fits, 2013; 1(2): 1-10.
CHIONCEL O, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. European Journal of Heart Failure, 2017; 19(12): 1574-1585.
FREITAS AE e CIRINO RHD. Manejo ambulatorial da insuficiência cardíaca crônica. Revista médica da UFPR, 2017; 4(3): 123-136.
GARD E, et al. Management of heart failure with preserved ejection fraction. Aust Prescr, 2020; 43(1): 1-6.
GREENE SJ, et al. Medical Therapy for Heart Failure with Reduced Ejection Fraction: The CHAMP-HF Registry. Journal of the American College of Cardiology, 2018; 72(4): 351-366.
GROOTE P, et al. Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey. European Journal of Heart Failure, 2007; 9(12): 1205-1211.
KOMAJDA M, et al. Physicians’ adherence to guidelinerecommended medications i heart failure with reduced ejection fraction: data from the QUALIFY global survey. European Journal of Heart Failure, 2016; 18(5): 514-22.
LATADO AL, et al. Tendência da Mortalidade por Insuficiência Cardíaca em Salvador, Bahia, Brasil. Arquivos Brasileiros de Cardiologia, 2005; 85(5): 1-6.
MANN DL, et al. Braunwald tratado de doenças cardiovasculares. 10ed. Rio de Janeiro: Elsevier, 2018; 34p.
JAMESON J, et al. Insuficiência Cardíaca e Cor pulmonale- Medicina Interna de Harrison. 18 ed. Porto Alegre: McGraw Hill, 2013; 1913p.
MARTI CN, et.al. Medication dosing for heart failure with reduced ejection fraction — opportunities and challenges. European Journal of Heart Failure, 2019; 21(3): 286-296.
MOURA LZ, et al. Uso de betabloqueadores em pacientes maiores de 65 anos com insuficiência cardíaca sistólica. Revista médica UFPR, 2016; 3(3): 1-6.
MURAD RV, et al. Insuficiência cardíaca: o benefício da terapia com betabloqueadores. Revista Caderno de Medicina, 2018; 1(1): 1-11.
NOGUEIRA PR, et. al. Perfil Epidemiológico, Clínico e Terapêutico da Insuficiência Cardíaca em Hospital Terciário. Arquivo Brasileiro de Cardiologia, 2010; 95(3): 1-7.
POELZL G, et. al. Dose Matters! Optimisation of Guideline Adherence Is Associated With Lower Mortality in Stable Patients With Chronic Heart Failure. Int J Cardiol, 2015; 175(1): 83-9.
SAVARESE G, et.al. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. European Journal of Heart Failure, 2018; 20(9): 1326-1334.
Sociedade Brasileira de Cardiologia. Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda. Departamento de Insuficiência Cardíaca (DEIC) e Sociedade Brasileira de Cardiologia (SBC), 2018; 441-461.
SOLAL AC, et.al. Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricular Ejection fraction: The FUTURE survey. Archives of Cardiovascular Disease, 2012; 105(6): 355-65.
SOUZA MP, et al. Perfil epidemiológico de idosos com Insuficiência Cardíaca na Unidade de Terapia Intensiva. Revista Enfermagem Contemporânea, 2017; 6(1): 1-7.
VITÓRIA DA CONQUISTA. Secretaria Municipal de Saúde. 2018. Portaria 017/2018 – GAB/ SMS. Institui o protocolo de uso de Metoprolol no âmbito da Secretaria de saúde do município de Vitória da Conquista-Bahia. Diário oficial de Vitoria da Conquista Edição 2.088, p.41 de 58, 28 de março de 2018.
ZUBAID M, et al. Implementation of Guideline-Recommended Therapies for Patients with Heart Failure and Reduced Ejection Fraction: A Regional Arab Middle East Experience. Angiology, 2020; 71(5): 431-437.